myEarthLink
News

Weather  

 

The Weather Channel
Mostly Cloudy
70° F
New York, NY
Mostly Cloudy
Hi: 67° / Lo: 61°

Sports   edit

nhl - Scoreboard [hide]

Friday, October 20, 2017
San Jose Sharks (3-3-0) at
Final
No Games Scheduled
Friday, October 27, 2017
Ottawa Senators (4-1-3) at
Preview

nba - Scoreboard [hide]

Monday, October 23, 2017
Final
No Games Scheduled
Wednesday, October 25, 2017
Preview

nfl - Scoreboard [hide]

Sunday, October 22, 2017
Final
Sunday, October 15, 2017
Final
No Games Scheduled
Sunday, October 29, 2017
Preview

mlb - Scoreboard [hide]

Saturday, October 21, 2017
New York Yankees (91-71) at
Final
No Games Scheduled
Thursday, March 29, 2018
Preview

Market Update  

- By Emma Court Ultimately, consumers aren't Equifax's main business -- selling services to other businesses is Equifax Inc.'s massive data breach took several weeks to become public, likel...
More

MarketWatch

 
Sign In to get personalized news, weather and more at myEarthLink.
 

Printable View

The Latest: FDA advisers endorse gene therapy for blindness
Dr. Barry Byrne listens to testimony concerning the approval of a potentially breakthrough drug for a form of blindness during a meeting of the The Cellular, Tissue and Gene Therapies advisory committee, Thursday, Oct. 12. 2017, at the FDA in Silver Spring, Md. (AP Photo - Nick Wass)
From Associated Press
October 12, 2017 2:33 PM EST

SILVER SPRING, Md. (AP) — The Latest on an FDA panel's discussion on a gene therapy treatment for blindness (all times local):

3:19 p.m.

U.S. health advisers have endorsed an experimental approach to treating inherited blindness, setting the stage for the likely approval of an innovative new genetic medicine.

A panel of experts to the Food and Drug Administration voted unanimously in favor of Spark Therapeutics' injectable therapy, which aims to improve vision in patients with a rare mutation that gradually destroys normal vision. The vote amounts to a recommendation to approve the therapy.

The FDA has until mid-January to make its decision. The agency does not have to follow the panel's recommendation, though it often does.

If approved, the treatment called Luxturna would be the first gene therapy in the U.S. for an inherited disease, offering hope to patients with a variety of genetic disorders.

___

8:30 a.m.

U.S. health advisers are reviewing a novel treatment for a rare form of inherited blindness, potentially setting the stage for the launch of a groundbreaking new genetic medicine.

The Food and Drug Administration panel will vote Thursday on whether to recommend approval of Philadelphia-based Spark Therapeutics' treatment, which aims to improve vision in some patients with hereditary blindness by replacing a defective gene that affects vision.

The FDA is not required to follow the group's recommendation, but such deliberations are generally the final step in the agency's decision-making process. The FDA has until mid-January to decide. If approved, it would be the first gene therapy in the U.S. for an inherited disease, offering hope to patients with a variety of related conditions.

Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.